Trade

with

Catalyst Pharmaceutical Partners Inc
(NASDAQ: CPRX)
AdChoices
2.68
+0.18
+7.20%
After Hours :
2.64
-0.04
-1.49%

Open

2.52

Previous Close

2.50

Volume (Avg)

530.69k (1.34M)

Day's Range

2.51-2.75

52Wk Range

1.29-3.49

Market Cap.

180.01M

Dividend Rate ( Yield )

-

Beta

0.84

Shares Outstanding

67.17M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -12.15M

    • Market Cap.

    • 180.01M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.84

    • Forward P/E

    • -9.57

    • Price/Sales

    • -

    • Price/Book Value

    • 4.37

    • Price/Cash flow

    • -11.98

      • EBITDA

      • -10.29M

      • Return on Capital %

      • -48.83

      • Return on Equity %

      • -55.95

      • Return on Assets %

      • -48.83

      • Book Value/Share

      • 0.61

      • Shares Outstanding

      • 67.17M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 7.50

        • Credit Rating

        • -

        • Analysts

        • 4

        • EPS Estimate

        • -0.28

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 64.72

            • Pre-Tax Margin

            • -

            • 13.77

            • Net Profit Margin

            • -

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 19.39

              • 1.52

              • Quick Ratio

              • 19.04

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.12

              • 1.91

              • Book Value/Share

              • 0.61

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -9.41

                • 65.36

                • P/E Ratio 5-Year High

                • -14.02

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.42

                • 19.71

                • Price/Sales Ratio

                • -

                • 3.63

                • Price/Book Value

                • 4.00

                • 3.39

                • Price/Cash Flow Ratio

                • -11.98

                • 21.83

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -55.95

                    (-78.10)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -48.83

                    (-65.90)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -55.95

                    (-78.10)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • -

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -10.31M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -11.98
                  Ownership

                  Institutional Ownership

                  33.28%

                  Top 10 Institutions

                  28.70%

                  Mutual Fund Ownership

                  14.01%

                  Float

                  77.07%

                  5% / Insider Ownership

                  10.46%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • AST Federated Aggressive Growth

                  •  

                    1,613,500

                  • 0.00

                  • 2.40

                  • Federated Kaufmann Small Cap Fund

                  •  

                    1,502,600

                  • -3.99

                  • 2.24

                  • Franklin Biotechnology Discovery Fund

                  •  

                    914,000

                  • 16.82

                  • 1.36

                  • Vanguard Total Stock Mkt Idx

                  •  

                    898,480

                  • 0.00

                  • 1.34

                  • Vanguard Extended Market Index Fund

                  •  

                    646,160

                  • 0.00

                  • 0.96

                  • Vanguard Instl Total Stock Market Index

                  •  

                    276,282

                  • 0.00

                  • 0.41

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    212,099

                  • 0.00

                  • 0.32

                  • iShares Micro-Cap

                  •  

                    179,415

                  • 0.00

                  • 0.20

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    3,185,000

                  • +87.13%

                  • 4.74

                  • Baker Bros Advisors LLC

                  •  

                    2,223,053

                  • +290.11%

                  • 3.31

                  • Orbimed Advisors, LLC

                  •  

                    1,895,000

                  • 0.00%

                  • 2.82

                  • Vanguard Group, Inc.

                  •  

                    1,788,642

                  • +9.41%

                  • 2.66

                  • Opaleye Management Inc

                  •  

                    1,378,584

                  • 0.00%

                  • 2.05

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Growth

                  Catalyst Pharmaceutical Partners, Inc. was incorporated in Delaware in July 2006. The Company is a development-stage specialty pharmaceutical company focused on the development and commercialization of prescription drugs targeting ra...morere (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. It has three pharmaceutical products in development namely Firdapse(tm), CPP-115 and CPP-109. In October 2012, the Company licensed the North American rights to Firdapse(tm), a proprietary form of amifampridine phosphate, or chemically known as 3,4-diaminopyridine phosphate, from BioMarin Pharmaceutical Inc. (BioMarin). CPP-115 is in the early stages of developing CPP-115, a GABA aminotransferase inhibitor that, based on its pre-clinical studies to da...morete, it believe is a more potent form of vigabatrin, but may have fewer side effects than those associated with vigabatrin. CPP-109 was evaluated for the treatment of cocaine addiction. An academic investigator proof-of-concept study evaluating the use of CPP-109 for the treatment of Tourette syndrome is currently ongoing. The Company also competes against biotechnology companies, universities, government agencies, and other research institutions in the development of substance abuse treatments, technologies and processes. The pharmaceutical industry is intensely competitive, and any product candidate developed or licensed by the Company would likely compete with existing drugs and therapies. In the United States, drugs are subject to rigorous regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA, and implementing regulations, as well as other federal and state statutes.lessless

                  Key People

                  Patrick J. McEnany

                  CEO/Chairman of the Board/Director/President/Co-Founder

                  Dr. Hubert E. Huckel,M.D.

                  Director/Co-Founder

                  Alicia Grande

                  CFO/Chief Accounting Officer/Treasurer/Vice President

                  M. Douglas Winship

                  Vice President, Divisional

                  Dr. Bernardino Mosquera, M.D.

                  Vice President, Divisional

                  • Catalyst Pharmaceutical Partners Inc

                  • 355 Alhambra Circle

                  • Coral Gables, FL 33134

                  • USA.Map

                  • Phone: +1 305 529-2522

                  • Fax: +1 305 529-0933

                  • catalystpharma.com

                  Incorporated

                  2006

                  Employees

                  7

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: